One of a host of new methods used for diagnosis of and screening for COVID-19, there are still hurdles to widespread adoption of breath testing for the disease.
Initiatives to develop commercial breath diagnostic systems reveal that developers are trying out lab-based mass spec systems and portable electronic noses.
The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.
The firm believes the IsoPSA technology is superior to competitors, but clinicians argue that a lack of comparative studies could hamper adoption of all these tests.
